ArticleJournal of molecular neuroscience : MN2014
Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.
Article in Journal of molecular neuroscience : MN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Antimicrobial Neuropeptides and Their Receptors: Immunoregulator and Therapeutic Targets for Immune Disorders.Molecules (Basel, Switzerland) · 2025Review
- miR-30c affects the pathogenesis of ulcerative colitis by regulating target gene VIP.Scientific reports · 2024Article
- Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications.Frontiers in pharmacology · 2024Review
- Guardians of the gut: influence of the enteric nervous system on the intestinal epithelial barrier.Frontiers in medicine · 2023Review
- Macrophage orchestration of epithelial and stromal cell homeostasis in the intestine.Journal of leukocyte biology · 2022Review
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis.Frontiers in pharmacology · 2021Article
- Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells.World journal of gastroenterology · 2020Review
- Vasoactive Intestinal Polypeptide (VIP) in the Intestinal Mucosal Nerve Fibers in Dogs with Inflammatory Bowel Disease.Animals : an open access journal from MDPI · 2020Article
- An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.Frontiers in endocrinology · 2019Review
- Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system.F1000Research · 2019Review
- Immunomodulatory Roles of PACAP and VIP: Lessons from Knockout Mice.Journal of molecular neuroscience : MN · 2018Review
- Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats.World journal of gastroenterology · 2018Article
- Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.Molecular pharmaceutics · 2017Article
- Sensory neuron regulation of gastrointestinal inflammation and bacterial host defence.Journal of internal medicine · 2017Review
- LRRK2: An Emerging New Molecule in the Enteric Neuronal System That Quantitatively Regulates Neuronal Peptides and IgA in the Gut.Digestive diseases and sciences · 2017Article
- Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis.PloS one · 2017Article
- The Role of Neuropeptides in Mouse Models of Colitis.Journal of molecular neuroscience : MN · 2016Review
- Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP).Journal of molecular neuroscience : MN · 2015Article
- The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease.Frontiers in immunology · 2015Review
- Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection against colitis in mice.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
VIP is highly expressed in the colon and regulates motility, vasodilatation, and sphincter relaxation. However, its role in the development and progress of colitis is still controversial. Our aim was to determine the participation of VIP on dextran sodium sulfate (DSS)-induced colonic mucosal inflammation using VIP(-/-) and WT mice treated with VIP antagonists. Colitis was induced in 32 adult VIP(-/-) and 14 age-matched WT litter-mates by giving 2.5 % DSS in the drinking water. DSS-treated WT mice were injected daily with VIP antagonists, VIPHyb (n = 22), PG 97-269 (n = 9), or vehicle (n = 31). After euthanasia, colons were examined; colonic cytokines mRNA were quantified. VIP(-/-) mice were remarkably resistant to DSS-induced colitis compared to WT. Similarly, DSS-treated WT mice injected with VIPHyb (1 μM) or PG 97-269 (1 nM) had significantly reduced clinical signs of colitis. Furthermore, colonic expression of IL-1ϐ, TNF-α, and IL-6 was significantly lower in VIP(-/-) and VIPHyb or PG 97-269 compared to vehicle-treated WT. Genetic deletion of VIP or pharmacological inhibition of VIP receptors resulted in resistance to colitis. These data demonstrate a pro-inflammatory role for VIP in murine colitis and suggest that VIP antagonists may be an effective clinical treatment for human inflammatory bowel diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.